DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
With advanced equipment and expanded services, Laredo's Women's Imaging Center addresses diagnostic delays, offering ...
Recent screening guidelines have raised some concern among patients, with doctors saying if you feel something is off, ask ...
The Galleri test — which isn’t covered by insurance — doesn’t come cheap. At $949 a pop, it’s out of the price range of most ...
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
The American Cancer Society has released its latest report on cancer in the United States, revealing both encouraging and concerning trends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback